Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Serivces

###### Food and Drug Administration

          - [Docket No. FDA-2009-N-0664]

# AGENCY:

 Food and Drug Administration.

# ACTION:

 Notice.

# SUMMARY:

 The Food and Drug Administration (FDA) is announcing a public workshop, co-sponsored with the Infectious Diseases Society of America (IDSA), regarding scientific issues in the development of molecular and other tests for the diagnosis of respiratory infections, entitled “Advancing Clinical Development of Molecular and Other Diagnostic Tests for Respiratory Tract Infections.” The purpose of the public workshop is to provide an opportunity to share information and perspectives with health care providers, academia, and industry on various aspects of diagnostic test development for respiratory infections. Topics for discussion will include the role of emerging diagnostic tests in promoting appropriate use of antibiotics by physicians, the use of novel diagnostic tests in the study of new drugs for respiratory infections, and the possible contribution of biomarkers in the approach to treatment of respiratory infections.

*Date and Time*: The public workshop will be held on November 12, 2009, from 8 a.m. to 6 p.m. and on November 13, 2009, from 8 a.m. to 4:30 p.m.                    

*Location*: The public workshop will be held at the Hilton Washington DC North/Gaithersburg, The Ballrooms, 620 Perry Pkwy., Gaithersburg, MD 20877. Seating is limited and available only on a first-come, first-served basis.                    

*Contact Person*: Christine Kellerman, Center for Devices and Radiological Health, Food and Drug Administration, Office of In Vitro Diagnostic Devices, 10903 New Hampshire Ave., Building 66, rm. 5677, Silver Spring, MD 20993-0002, 301-796-5711.                    

*Registration*: To register electronically, e-mail registration information (including: Name, title, firm name, address, telephone, and fax numbers) to                         *Respdiagmtg@fda.hhs.gov*                         by November 8, 2009. Persons without access to the Internet can call 301-796-5711 to register. Registration is free for the public workshop. Interested parties are encouraged to register early because space is limited. Seating will be available on a first-come, first-served basis. Persons needing a sign language interpreter or other special accommodations should notify Christine Kellerman (see                         *Contact Person*) at least 7 days in advance. Additional information is also available at                         *http://www.fda.gov/​MedicalDevices/​NewsEvents/​WorkshopsConferences/​ucm181140.htm*.                    

# SUPPLEMENTARY INFORMATION:

## I. Background

New diagnostic technologies offer opportunities to guide the appropriate clinical use of anti-infective agents, facilitate the study of new anti-infective agents, and aid in tracking the spread of infectious diseases. To explore issues regarding the development and adoption of emerging diagnostic tests, FDA is announcing a public workshop, co-sponsored with IDSA to address scientific issues in the development of in vitro diagnostic tests for respiratory infections.

## II. Topics for Discussion at the Public Workshop

Topics to be discussed at the workshop include: 
    - Principles of clinical trial design and their application to studies of new diagnostics, or studies where new diagnostics and new drugs are investigated simultaneously;
    - Test characteristics for emerging tests that would promote clinical adoption and improve antibiotic stewardship;
    - Principles for including specific viral or bacterial pathogens in multiplex diagnostic test panels;
    - Discussion of approaches to developing a new molecular method when there is no “gold standard” reference method; and
    - The use of biomarkers in respiratory infections.

The input from this public workshop will help in developing topics for further discussion. The agency encourages individuals, patient advocates, industry, consumer groups, health care professionals, researchers, and other interested persons to attend this public workshop.

*Transcripts*: Transcripts of the public workshop may be requested in writing from the Freedom of Information Office (HFI-35), Food and Drug Administration, 5600 Fishers Lane, rm. 6-30, Rockville, MD 20857, approximately 20 working days after the public workshop at a cost of 10 cents per page. A link to the transcripts will also be available on the Internet at                     *http://www.fda.gov/​MedicalDevices/​NewsEvents/​WorkshopsConferences/​default.htm*                     approximately 45 days after the workshop.                

Dated: October 7, 2009.

Jeffrey Shuren,

Acting Director, Center for Devices and Radiological Health.

[FR Doc. E9-24828 Filed 10-14-09; 8:45 am]

BILLING CODE 4160-01-S